RVNC: Revance Therapeutics, Inc.
About
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Current Value
$3.921 Year Return
Current Value
$3.921 Year Return
Key Details
Market Cap
$394.43M
P/E Ratio
-1.96
1Y Stock Return
-47.99%
1Y Revenue Growth
15.33%
Dividend Yield
0.00%
Price to Book
-2.4
Strategies that include RVNC
Stock's related to RVNC
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ABX | 38.06% | $30.98B | +9.45% | 2.27% |
| LASR | 37.35% | $526.43M | -2.60% | 0.00% |
| PBI | 36.83% | $1.41B | +100.00% | 2.57% |
| FF | 30.66% | $227.57M | +21.57% | 4.55% |
| PSNL | 29.55% | $260.69M | +152.74% | 0.00% |
| KODK | 28.56% | $422.90M | +41.40% | 0.00% |
| FARO | 28.00% | $486.17M | +40.51% | 0.00% |
| SRRK | 27.99% | $2.61B | +134.91% | 0.00% |
| CYD | 27.89% | $364.46M | -2.94% | 4.26% |
| ALLO | 27.67% | $444.50M | -24.82% | 0.00% |
| RCEL | 27.54% | $321.96M | +27.43% | 0.00% |
| EVH | 26.95% | $1.39B | -58.46% | 0.00% |
| BIGC | 26.74% | $473.42M | -31.75% | 0.00% |
| TBPH | 26.59% | $487.81M | -3.50% | 0.00% |
| CDE | 26.57% | $2.66B | +143.96% | 0.00% |
| LC | 26.57% | $1.69B | +175.00% | 0.00% |
| PAG | 26.46% | $10.63B | +4.43% | 2.59% |
| CSV | 26.46% | $590.66M | +75.49% | 1.16% |
| SN | 26.45% | $13.84B | +118.64% | 0.00% |
| ASTH | 26.43% | $2.01B | +24.82% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WTW | -0.02% | $30.98B | +26.60% | 1.13% |
| ORKA | 0.08% | $780.47M | +82.82% | 0.00% |
| LMT | -0.08% | $126.40B | +18.99% | 2.36% |
| OBDC | -0.09% | $5.86B | +4.58% | 10.23% |
| JELD | -0.12% | $859.74M | -34.45% | 0.00% |
| MRK | -0.13% | $244.21B | -5.55% | 3.18% |
| VSTA | -0.17% | $204.94M | -39.33% | 0.00% |
| IMMR | 0.18% | $276.60M | +33.49% | 2.09% |
| OCX | -0.21% | $42.93M | -36.09% | 0.00% |
| FAST | -0.23% | $46.74B | +35.26% | 1.92% |
| IMXI | 0.24% | $651.21M | -1.55% | 0.00% |
| TRIN | 0.24% | $842.35M | -3.18% | 14.19% |
| DLB | -0.24% | $6.76B | -16.58% | 1.69% |
| FHI | -0.26% | $3.38B | +35.20% | 2.93% |
| CCEC | 0.26% | $1.02B | +28.03% | 3.26% |
| EDSA | -0.28% | $7.11M | -21.79% | 0.00% |
| AQN | 0.28% | $3.79B | -20.96% | 8.21% |
| FTNT | -0.29% | $69.59B | +72.67% | 0.00% |
| MERC | 0.30% | $416.61M | -37.89% | 4.82% |
| ABT | 0.32% | $203.16B | +14.93% | 1.88% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RILY | -24.55% | $145.72M | -79.86% | 20.75% |
| FTRE | -21.72% | $1.68B | -42.77% | 0.00% |
| STG | -18.05% | $35.67M | +7.92% | 0.00% |
| NATR | -16.39% | $295.06M | -7.42% | 0.00% |
| AXON | -15.59% | $46.53B | +167.14% | 0.00% |
| PG | -15.22% | $402.15B | +14.14% | 2.33% |
| JBLU | -13.94% | $2.07B | +41.57% | 0.00% |
| KHC | -12.99% | $36.98B | -10.45% | 5.23% |
| UTZ | -12.94% | $1.37B | +26.87% | 1.41% |
| RSG | -12.94% | $66.05B | +31.79% | 1.04% |
| TASK | -12.51% | $1.27B | +16.72% | 0.00% |
| ELF | -12.20% | $6.86B | +8.95% | 0.00% |
| CHD | -11.85% | $27.18B | +19.50% | 1.03% |
| TEM | -11.41% | $8.50B | 0.00% | 0.00% |
| GLP | -11.23% | $1.77B | +51.33% | 5.50% |
| SYPR | -10.95% | $32.23M | -26.32% | 0.00% |
| NTIC | -9.99% | $132.27M | +24.98% | 2.02% |
| ACGL | -9.82% | $36.00B | +16.84% | 0.00% |
| RNR | -9.70% | $13.74B | +23.09% | 0.58% |
| SRG | -9.66% | $221.13M | -55.94% | 0.00% |
ETF's related to RVNC
News
SeekingAlpha
Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.
Finnhub
EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER This EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER , dated November 19, 2024, is made by and among Crown Laboratories, Inc.,...
Finnhub
NEW YORK, Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. . Such investors are advised to contact Danielle Peyton at...
Yahoo
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of -5.71% and 11.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
NASHVILLE, Tenn., November 07, 2024--Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
Finnhub
SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER This SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER , dated November 1, 2024, is made by and among Crown Laboratories, Inc., a Delaware...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.